Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top 15 Style Creators Changing the Business - 2Understanding climate change in America: Skepticism, dogmatism and personal experience
- 3Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- 4French high-speed train slams into truck, killing TGV driver
- 5Choosing the Ideal Bed for Quality Rest and Solace
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- Experience Arranging: Planning for Epic Excursions
- NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
- Choosing Moving Styles for Your Restroom Redesign
- Shipping: The Corridors of Trade and the Coming of Another Period
- Senegal limits foreign trips for officials as the fallout from Iran war deepens
- Which Instax Camera Would it be a good idea for you to Purchase?
- Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- Understanding Preschool Projects: An Extensive Aide
